CRNX - Crinetics Pharmaceuticals Inc
IEX Last Trade
53.03
0.330 0.622%
Share volume: 706,613
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$52.70
0.33
0.63%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-14 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 421.733 M | 384.880 M | 352.176 M | 314.009 M | 293.254 M | 641.537 M | 635.353 M | 978.153 M | |
| Current Assets | 416.285 M | 378.323 M | 345.184 M | 305.403 M | 284.810 M | 575.760 M | 574.153 M | 917.228 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 7.779 M | 9.961 M | 10.759 M | 9.281 M | 20.281 M | 21.107 M | 15.598 M | 16.267 M | |
| Short Term Investments | 7.779 M | 9.961 M | 10.759 M | 9.281 M | 20.281 M | 21.107 M | 15.598 M | 16.267 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 408.506 M | 368.362 M | 334.425 M | 296.122 M | 264.529 M | 554.653 M | 558.555 M | 900.961 M | |
| Total Non-current Assets | 5.448 M | 6.557 M | 6.992 M | 8.606 M | 8.444 M | 65.777 M | 61.200 M | 60.925 M | |
| Property Plant Equipment | 3.152 M | 3.564 M | 3.500 M | 3.266 M | 3.223 M | 9.764 M | 10.881 M | 11.865 M | |
| Other Assets | 1.796 M | 1.693 M | 2.191 M | 4.039 M | 3.921 M | 54.713 M | 49.019 M | 47.760 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 421.733 M | 384.880 M | 352.176 M | 314.009 M | 293.254 M | 641.537 M | 635.353 M | 978.153 M | |
| Total liabilities | 35.568 M | 33.508 M | 35.848 M | 33.679 M | 39.138 M | 93.789 M | 96.247 M | 103.220 M | |
| Total current liabilities | 26.115 M | 24.556 M | 27.723 M | 26.321 M | 32.610 M | 40.463 M | 43.942 M | 51.767 M | |
| Accounts Payable | 17.132 M | 13.495 M | 15.351 M | 16.296 M | 20.825 M | 21.935 M | 23.196 M | 28.683 M | |
| Other liabilities | 6.888 M | 6.652 M | 6.101 M | 5.615 M | 5.072 M | 5.144 M | 4.750 M | 4.741 M | |
| Current long term debt | 0.000 | 1.022 M | 0.000 | 1.079 M | 1.109 M | 3.989 M | 0.000 | 5.792 M | |
| Long term debt | 2.565 M | 2.300 M | 2.024 M | 1.743 M | 1.456 M | 48.182 M | 47.555 M | 46.712 M | |
| Other liabilities | 6.888 M | 6.652 M | 6.101 M | 5.615 M | 5.072 M | 5.144 M | 4.750 M | 4.741 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 386.165 M | 351.372 M | 316.328 M | 280.330 M | 254.116 M | 547.748 M | 539.106 M | 874.933 M | |
| Common stock | 52.522 M | 53.768 M | 53.926 M | 53.908 M | 54.275 M | 56.808 M | 67.293 M | 72.289 M | |
| Retained earnings | -352.257 M | -394.182 M | -439.173 M | -485.168 M | -536.147 M | -593.605 M | -653.702 M | -720.632 M |